Competition, page-25

Cu64/67 is owned by Clarity (NSW based). SAR-bisPSMA - Next-Generation, Highly Targeted Prostate Cancer Theranostic - Clarity (claritypharmaceuticals.com)

They are not listed, hadn't heard they were planning for ASX listing.

Cu64 has theoretical advantages. With a 12h half life, you can do serial imaging - you get an idea of disease sites the injection gets to after a few hours, then a day later you can see if those sites retained the tracer and potentially even stretch it out to 2 days.
This is useful for estimating dosimetry and the actual radiation dose delivered to sites of disease.

With Ga68 (~1h half life), you cannot assess for retention beyond 3-4h, so even if a disease site takes up the tracer very strongly, it might dissociate after 8 hours and you'd never know. So if you were to administer Lu-177 bound to the ligand, there would only be treatment at the disease site for a short while (ie. may not work).

Same with Zr89 btw (TLX using this for TLX250 cdx, even longer half life at 78h.)
hope that makes senes